OBJECTIVES: The medical community expressed concerns of unintended negative consequences regarding pain management as a result of rescheduling hydrocodone combination products (HCPs). This study was conducted to evaluate the impact of HCP rescheduling on Texas physicians’ pain management prescribing. METHODS: An electronic cross-sectional survey (via Qualtrics) was administered to physicians of the Texas Medical Association. Physicians were asked whether: (a) rescheduling would alter their pain-management; (b) increased administrative burden (i.e., special pad requirement) for schedule-IIs [C-IIs]) would prevent them from prescribing C-II drugs and; (c) ordering C-II prescription pads will deter them from prescribing HCPs (1=strongly disagree; 7=strongly agree). Physicians’ future medication prescribing (HCPs, acetaminophen/codeine or tramadol) for managing acute and chronic non-cancer pain (NCP) after rescheduling was also assessed by practice type  (primary care/emergency/pain management), race (white/non-white) and age (≤50 years/>50 years). Chi-square analyses were used to address the study objective. RESULTS: A total of 1176 usable responses were obtained. Approximately 59% of respondents agreed that rescheduling would alter their pain management, 33% agreed that administrative burden would prevent them from prescribing C-II opioids and 24% agreed that ordering prescription pads will deter them from prescribing HCPs. Chi-square analyses indicated that physicians’ medication prescribing for acute NCP was significantly associated with practice type (χ= 71.11, p<0.0001), race (χ= 13.13, p=0.001) and age (χ= 8.50, p=0.014). Prescribing for chronic NCP was significantly associated with practice type (χ= 53.77, p<0.0001). Overall, physicians were most likely to prescribe acetaminophen/codeine for acute NCP (33.56%) and tramadol for chronic NCP (40.43%) after rescheduling. CONCLUSIONS: After rescheduling, physicians were more likely to prescribe acetaminophen/codeine or tramadol over HCPs for NCP management. This may result in reduced efficacy, adverse events and drug-drug interactions associated treatment alternatives in addition to added clinical and economic burden. Future studies evaluating provider behaviors and NCP management outcomes are warranted.